Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting
Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting
Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…Abstract Number: 460 • 2019 ACR/ARP Annual Meeting
Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels
Background/Purpose: Patients with rheumatoid arthritis (RA) display a higher infertility prevalence compared with the general population. Disease-related inflammation and RA treatments are likely to be…Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting
Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…Abstract Number: 470 • 2019 ACR/ARP Annual Meeting
Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis
Background/Purpose: While treat-to-target strategies can dramatically reduce inflammation in RA, persistently high levels of fatigue are present in many patients and represent an important unmet need.…Abstract Number: 1859 • 2019 ACR/ARP Annual Meeting
Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients
Background/Purpose: A tender joint count is part of most disease activity scores and remission criteria in rheumatoid arthritis (RA). A recent study in established RA…Abstract Number: 2870 • 2019 ACR/ARP Annual Meeting
Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response
Background/Purpose: Synovial B cell aggregates in patients with early Rheumatoid Arthritis (RA) have been associated with disease severity and radiographic progression. Here, we analysed the…Abstract Number: 471 • 2019 ACR/ARP Annual Meeting
When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA
Background/Purpose: Although overwhelming fatigue is common at the onset of RA, some patients continue to experience debilitating high levels of fatigue that impact mood, interfere with work…Abstract Number: 1885 • 2019 ACR/ARP Annual Meeting
A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia
Background/Purpose: Based on a unique cohort of clinically suspect arthralgia (CSA) patients, we analysed which combinations of MRI-features at onset were predictive for Rheumatoid Arthritis…Abstract Number: 2871 • 2019 ACR/ARP Annual Meeting
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established…Abstract Number: 72 • 2018 ACR/ARHP Annual Meeting
Altered Serologic Responses to Epstein Barr Virus Precede Clinical Disease Development in Rheumatoid Arthritis
Background/Purpose: EBV infects B cells and is associated with several autoimmune diseases, including RA. Prior studies have shown that patients with active classified RA…Abstract Number: 1492 • 2018 ACR/ARHP Annual Meeting
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Background/Purpose: Available clinical tools do not adequately identify treatment non-responders in early rheumatoid arthritis (RA) leading to delayed disease control. Tools informed by molecular phenotype…Abstract Number: 310 • 2018 ACR/ARHP Annual Meeting
The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA
Background/Purpose: The identification of erosions plays a critical role in the management of RA, as the presence of erosions denotes more aggressive disease requiring more…Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 18
- Next Page »